ArticleCureus2025
Comparison of Letrozole Versus Clomiphene Citrate Combined With Human Menopausal Gonadotropin in Women With Clomiphene-Resistant Anovulatory Infertility Undergoing Intrauterine Insemination: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Millions of people of reproductive age worldwide struggle with infertility. Treatments such as controlled ovarian hyperstimulation and intrauterine insemination (IUI) are commonly used to address various causes of infertility. Medications such as clomiphene citrate (CC) and letrozole, when combined with human menopausal gonadotropin (HMG), have been shown to improve pregnancy rates and reduce treatment costs. Objective This study aimed to compare the effect of minimal stimulation using HMG with either CC or letrozole for ovulation induction in women with CC-resistant anovulatory infertility. It also assessed the impact of these combinations on follicular development and endometrial thickness. Materials and methods This retrospective cohort study included data from 84 infertile women diagnosed with polycystic ovary syndrome (PCOS). Participant records were retrieved from the hospital database at AIIMS, Raipur, India, covering the period from April 2021 to August 2022. Women were divided into two groups based on their treatment: one group received CC 100 mg and the other letrozole 5 mg, both in combination with HMG administered on alternate days. Forty-two women received letrozole + HMG and 40 received CC + HMG. Two participants in the CC group were excluded due to the development of four dominant follicles. Transvaginal ultrasound was performed on alternate days until follicles exceeded 17 mm. IUI was carried out 36 hours after HCG administration. Fourteen days later, a urinary pregnancy test was done if the participant had not yet menstruated. The clinical pregnancy rates were compared between the two groups. Results There was no significant difference between the two groups in terms of mean follicular diameter, number of dominant follicles, endometrial thickness, HMG dosage required, or the number of days to achieve dominant follicle formation. The IUI outcomes were also comparable in both groups. Conclusion The study concludes that both letrozole and CC, when combined with HMGs, are equally effective in inducing ovulation and achieving successful IUI outcomes in women with CC-resistant anovulatory infertility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.